Shenzhen Bioeasy Biotechnology Co., Ltd. (SHE:300942)
China · Delayed Price · Currency is CNY 6.72
-0.18 (-2.61%)
Jun 2, 2026, 3:04 PM CST
SHE:300942 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 260.18 | 251.88 | 221.82 | 243.57 | 676.32 | 583.14 |
Other Revenue | 11.35 | 11.35 | 2.43 | 10.54 | 10.58 | 14.4 |
| 271.53 | 263.23 | 224.25 | 254.11 | 686.9 | 597.54 | |
Revenue Growth (YoY) | 14.51% | 17.38% | -11.75% | -63.01% | 14.95% | 131.20% |
Cost of Revenue | 99.16 | 97.18 | 68.15 | 157.92 | 345.01 | 171.38 |
Gross Profit | 172.37 | 166.04 | 156.1 | 96.19 | 341.89 | 426.16 |
Selling, General & Admin | 109.54 | 104.78 | 95.23 | 151.18 | 151.19 | 100.05 |
Research & Development | 42.95 | 41.45 | 40.45 | 53.14 | 111.42 | 72.43 |
Other Operating Expenses | -1 | -0.6 | -4.3 | 3.52 | 2.51 | 3.16 |
Operating Expenses | 158.45 | 150.55 | 139.65 | 210.66 | 269.13 | 178.05 |
Operating Income | 13.91 | 15.5 | 16.45 | -114.47 | 72.76 | 248.1 |
Interest Expense | -26.79 | -26.49 | -18.67 | -10.63 | -4.08 | -2.38 |
Interest & Investment Income | 7.78 | 10.21 | 8.33 | 7.56 | 6.24 | 6.6 |
Currency Exchange Gain (Loss) | -1.05 | -1.05 | 2.65 | 6.03 | 9.23 | -4.14 |
Other Non Operating Income (Expenses) | -7.37 | -0.16 | -0.18 | -0.88 | -0.22 | -0.67 |
EBT Excluding Unusual Items | -13.52 | -1.99 | 8.59 | -112.39 | 83.93 | 247.51 |
Gain (Loss) on Sale of Investments | -5.91 | -8.34 | -3.98 | -54.08 | - | 5.21 |
Gain (Loss) on Sale of Assets | 11.97 | 12.21 | 2.28 | 2.81 | 1.43 | - |
Asset Writedown | 0.17 | 0.17 | -1.02 | -26.15 | -1.95 | -0 |
Other Unusual Items | 12.51 | 11.23 | 13.7 | 12.01 | 11.47 | 15.32 |
Pretax Income | 5.23 | 13.29 | 19.69 | -177.8 | 94.89 | 268.04 |
Income Tax Expense | -3.98 | -2.18 | 3.07 | 7.19 | 12.22 | 31.57 |
Earnings From Continuing Operations | 9.21 | 15.47 | 16.62 | -184.98 | 82.66 | 236.47 |
Minority Interest in Earnings | -2.38 | -1.72 | 0.5 | 0.08 | 0.3 | 0.04 |
Net Income | 6.83 | 13.74 | 17.12 | -184.91 | 82.97 | 236.51 |
Net Income to Common | 6.83 | 13.74 | 17.12 | -184.91 | 82.97 | 236.51 |
Net Income Growth | -67.29% | -19.71% | - | - | -64.92% | 261.38% |
Shares Outstanding (Basic) | 459 | 458 | 428 | 402 | 395 | 394 |
Shares Outstanding (Diluted) | 459 | 458 | 428 | 402 | 395 | 394 |
Shares Change (YoY) | 7.11% | 7.06% | 6.45% | 1.75% | 0.23% | 8.42% |
EPS (Basic) | 0.01 | 0.03 | 0.04 | -0.46 | 0.21 | 0.60 |
EPS (Diluted) | 0.01 | 0.03 | 0.04 | -0.46 | 0.21 | 0.60 |
EPS Growth | -69.46% | -25.00% | - | - | -65.00% | 233.33% |
Free Cash Flow | -7.93 | 20.97 | -139.85 | -165.89 | -24.29 | 175.92 |
Free Cash Flow Per Share | -0.02 | 0.05 | -0.33 | -0.41 | -0.06 | 0.45 |
Dividend Per Share | 0.025 | 0.025 | 0.017 | - | 0.021 | 0.249 |
Dividend Growth | 41.51% | 41.51% | - | - | -91.49% | 453.33% |
Gross Margin | 63.48% | 63.08% | 69.61% | 37.85% | 49.77% | 71.32% |
Operating Margin | 5.12% | 5.89% | 7.34% | -45.05% | 10.59% | 41.52% |
Profit Margin | 2.51% | 5.22% | 7.63% | -72.77% | 12.08% | 39.58% |
Free Cash Flow Margin | -2.92% | 7.97% | -62.36% | -65.29% | -3.54% | 29.44% |
EBITDA | 47.52 | 45.1 | 30.04 | -98.56 | 84.22 | 257.12 |
EBITDA Margin | 17.50% | 17.13% | 13.40% | -38.79% | 12.26% | 43.03% |
D&A For EBITDA | 33.6 | 29.6 | 13.59 | 15.91 | 11.46 | 9.01 |
EBIT | 13.91 | 15.5 | 16.45 | -114.47 | 72.76 | 248.1 |
EBIT Margin | 5.12% | 5.89% | 7.34% | -45.05% | 10.59% | 41.52% |
Effective Tax Rate | - | - | 15.59% | - | 12.88% | 11.78% |
Revenue as Reported | 271.53 | 263.23 | 224.25 | 254.11 | 686.9 | 597.54 |
Advertising Expenses | - | 0.52 | 0.13 | 0.96 | - | - |